anti-NKp30/anti-CD38 bispecific NK-cell engager (Compass Therapeutics)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-NKp30/anti-CD38 bispecific NK-cell engager (Compass Therapeutics)

Drug Alias Nameanti-NKp30/anti-CD38 bispecific antibody (Compass Therapeutics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionNatural killer cell p30-related protein agonistsLymphocyte differentiation antigen CD38 modulators

TargetsLymphocyte differentiation antigen CD38Natural killer cell p30-related protein

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCompass Therapeutics LLC

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCompass Therapeutics LLC

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A